FDA Plans PCAC Meeting Before End of February 2027 for Five Peptides

According to FDA's advisory committee page, the meeting agenda lists exactly those five substances "being considered for inclusion on the 503A bulks list.

" FDA states it "intends to publish a Federal Register notice and establish a docket for public comment on this meeting in the near future.

" Meeting materials and a webcast link will be posted "no later than two business days before the meeting," and the public may participate virtually. Open public hearing slots will be explained in the forthcoming Federal Register notice.

Important: As of November 9, 2026, no meeting date, time, location, or Federal Register docket has been published. Researchers and compliance teams monitoring this process should check FDA.gov and regulations.gov for updates.

This February 2027 meeting follows a parallel track established in 2026.

In April 2026, Orrick reported that FDA would remove 12 peptides from Category 2 after nominators withdrew nominations and scheduled PCAC meetings for July 23–24, 2026 and before the end of February 2027; Orrick also noted that GHK-Cu was removed from Category 1.

FDA's July 2026 PCAC page lists seven substances for that meeting, and FDA's February 2027 PCAC page lists the five substances now under review.

The first PCAC meeting occurred July 23–24, 2026, reviewing BPC-157, TB-500, epitalon, KPV, MOTS-c, semax, and emideltide (DSIP). The committee voted in favor of six (not emideltide).

In October 2026, HHS issued a draft interim enforcement-discretion policy (Federal Register October 30, 2026, FR Doc 2026-22192) covering only those six, while FDA pursues rulemaking to add them to the official 503A bulks list.

That HHS policy does not cover any of the five substances scheduled for the February 2027 PCAC meeting.

Four of the five substances now scheduled for February 2027 PCAC review (LL-37, Dihexa, Melanotan II, and PEG-MGF) appear on FDA's "nominated but withdrawn" list, having been withdrawn from Category 2.

GHK-Cu has a more complex status: injectable GHK-Cu was withdrawn from Category 2 and appears on FDA's "nominated but withdrawn" list; non-injectable GHK-Cu was removed from Category 1 on April 22, 2026 and is being added back to Category 1 per FDA's May 14, 2026 categories document.

See our timeline and analysis: Research Peptide Regulatory Timeline (2026), FDA Peptide Reclassification (2026), and USP Statement on HHS Peptide Policy.

FDA lists five bulk drug substances in the meeting agenda. Below is each substance's name as listed by FDA, its current status in FDA's categories document, and the safety concerns FDA has published:

Substance	Current FDA List Status	FDA's Stated Safety Concern Summary	Covered by HHS Oct 2026 Policy?
Cathelicidin (LL-37)	Nomination withdrawn; removed from category 2 (April 2026)	May pose risk for immunogenicity for certain routes; may have complexities with regard to peptide-related impurities and API characterization; FDA lacks sufficient safety-related information; nonclinical research findings suggest detrimental effects on male reproduction and that this drug can be protumorigenic in some tissues	No
GHK-Cu	Injectable routes: nomination withdrawn (formerly category 2). Non-injectable routes: category 1 per FDA's May 14, 2026 list	For injectable routes: may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities; limited human data to inform safety considerations	No
Dihexa acetate	Nomination withdrawn; removed from category 2 (April 2026)	FDA has not identified any human exposure data via any route of administration; lacks important safety information	No
Melanotan II	Nomination withdrawn; removed from category 2 (April 2026)	Immunogenicity risk due to aggregation or impurities; published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism	No
Mechano Growth Factor, Pegylated (PEG-MGF)	Nomination withdrawn; removed from category 2 (April 2026)	May pose significant risk for immunogenicity; may have complexities with regard to peptide-related impurities and API characterization; no human exposure data via any route	No

Sources: FDA's safety statements are from FDA's "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" page. All five substances appear under "Bulk drug substances nominated but withdrawn." Category status is from FDA's Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Updated May 14, 2026).

GHK-Cu Status Clarification

According to FDA's May 14, 2026 document, GHK-Cu (except for injectable routes) was removed from category 1 on April 22, 2026 because nominations were withdrawn. On May 5, 2026, one nominator clarified it intended to withdraw only the injectable route.

FDA's May 14, 2026 list shows GHK-Cu (except for injectable routes of administration) in category 1, and FDA states it intends to consult PCAC before the end of February 2027 on GHK-Cu.

The February 2027 meeting agenda lists "GHK-Cu" without route qualification, so the PCAC may review injectable routes specifically, or all routes depending on the scope FDA defines in the forthcoming Federal Register notice.

Note on Mechano Growth Factor

The FDA's May 14, 2026 categories document lists non-pegylated "Mechano growth factor (MGF)" in category 3 (nominated without adequate support). The February 2027 PCAC agenda lists "Mechano Growth Factor, Pegylated (PEG-MGF)" for review. These appear to be distinct entries; the PCAC meeting concerns only the pegylated form.

For research context on these substances, see our compound pages: LL-37, GHK-Cu, Dihexa, Melanotan II, and MGF.

Understanding the legal mechanics of advisory committee meetings is critical for researchers and procurement teams monitoring this process:

What the PCAC Can Do

• Make non-binding recommendations: The committee can vote to recommend that FDA add any or all of the five substances to the 503A bulks list, recommend against adding them, or provide no recommendation. Advisory committees make non-binding recommendations; FDA is not bound by them.
• Weigh evidence and hear public testimony: PCAC meetings include presentation of FDA staff briefing materials, expert testimony, public comment, and deliberation by committee members.

What the PCAC Cannot Do

• Change the 503A bulks list: Only FDA can add substances to 21 CFR 216.23 through notice-and-comment rulemaking. A PCAC vote, even a unanimous one, does not change the law or authorize compounding.
• Create enforcement discretion: PCAC recommendations do not create interim enforcement discretion policies. The October 2026 HHS enforcement-discretion policy for six peptides was a separate HHS decision following the July 2026 PCAC vote.
• Approve peptides as drugs: PCAC review does not constitute FDA drug approval. The five substances remain unapproved drug products regardless of PCAC vote outcomes.
• Address RUO catalog sales: 503A and the PCAC concern compounding; they do not create a pathway for selling these substances for human use.

The HHS enforcement discretion policy issued after the July 2026 PCAC meeting illustrates this: the PCAC voted in favor of six peptides, but it took separate HHS action—months later—to issue an interim enforcement-discretion policy. Even that policy is non-binding and does not add the peptides to the official bulks list. Formal rulemaking is still pending.

The official 503A bulks list at 21 CFR 216.23 currently contains only six substances—none of them peptides:

• Brilliant Blue G
• Cantharidin (topical use only)
• Diphenylcyclopropenone (topical use only)
• N-acetyl-D-glucosamine (topical use only)
• Squaric acid dibutyl ester (topical use only)
• Thymol iodide (topical use only)

Additions to this list require notice-and-comment rulemaking under section 503A(c) of the FD&C Act (21 U.S.C. 353a) / 21 CFR 216.23. A PCAC vote alone changes nothing legally. Until FDA completes rulemaking, none of the peptides under PCAC review—nor the six peptides covered by the October 2026 HHS enforcement discretion policy—are on the official 503A bulks list.

For 503A compounders, the October 2026 HHS enforcement-discretion policy provides interim guidance for six peptides (BPC-157, TB-500, epitalon, KPV, MOTS-c, semax).

For the five peptides scheduled for February 2027 PCAC review, no enforcement-discretion policy exists as of November 9, 2026, except that non-injectable GHK-Cu sits in category 1 under FDA's interim 503A bulks policy (where FDA generally does not intend to take action while it evaluates the substance).

Compounding with LL-37, injectable GHK-Cu, Dihexa, Melanotan II, or PEG-MGF outside the statutory criteria (USP/NF monograph or component of an approved drug) remains unauthorized under 503A until FDA issues rulemaking or separate enforcement discretion.

As of November 9, 2026, the PCAC meeting is scheduled only as "before the end of February 2027." FDA has not yet published a specific date, time, location, Federal Register notice, or public comment docket number. Here is what to watch:

1. Federal Register Notice and Public Comment Docket

FDA intends to publish a Federal Register notice establishing a docket for public comment on the meeting. That notice will announce:

• Meeting date, time, and location (virtual participation details)
• Instructions for submitting written comments to the docket
• Procedures for requesting to speak during the open public hearing segment
• Comment submission deadlines

Stakeholders—compounding pharmacies, patient advocacy groups, analytical laboratories, pharmacy associations, and quality standards organizations—will be able to submit written comments and request oral presentation slots once the docket opens. Monitor regulations.gov for the docket announcement.

2. FDA Briefing Documents (Two Business Days Before the Meeting)

FDA will post meeting materials and a webcast link "no later than two business days before the meeting." These materials typically include FDA staff briefing documents that review the nomination dossiers, safety data, clinical evidence (if any), and FDA's preliminary analysis. Briefing documents set out the issues FDA has identified for the committee's discussion.

3. PCAC Vote(s) and Meeting Summary

After the meeting, FDA will post a summary of the committee's recommendations.

4. Subsequent FDA Rulemaking (If Any)

After the PCAC meeting, FDA may propose to add some, all, or none of the five substances to the 503A bulks list through formal notice-and-comment rulemaking.

That rulemaking would include a separate Federal Register proposal, a public comment period, and a final rule. Only at the conclusion of that rulemaking process would substances be legally added to 21 CFR 216.23.

Alternatively, HHS may issue a separate enforcement-discretion policy for some or all of the five substances, as occurred after the July 2026 PCAC meeting. Such a policy would be interim guidance, not binding regulation.

5. Safety Signal or Product Quality Monitoring

HHS's October 2026 enforcement-discretion policy explicitly states that HHS may revisit the policy if a safety signal or product quality issue arises. The same principle would likely apply to any future enforcement-discretion policy covering the five substances under February 2027 PCAC review. Adverse event reports, product quality complaints, and compounded drug product surveillance will be important factors.

For updates, bookmark FDA's Pharmacy Compounding Advisory Committee page and regulations.gov. We will update our regulatory timeline when the Federal Register notice is published.

The February 2027 PCAC meeting and any subsequent 503A bulks list rulemaking apply to compounding pharmacy practice under section 503A of the FD&C Act. They do not apply to research-use-only catalog suppliers selling peptides for laboratory and analytical use.

However, FDA has warned online sellers that such labels do not settle the question.

In an August 24, 2026 warning letter to NuScience Peptides LLC, FDA stated that despite product labeling marketing the products "for laboratory, research, and analytical use" and "not intended for human or veterinary use," evidence from the company's website established that the products were intended to be drugs for human use.

The safety concerns FDA has published for LL-37, GHK-Cu, Dihexa, Melanotan II, and PEG-MGF—immunogenicity risks, lack of human exposure data, impurity characterization complexities, and serious adverse events in case reports—raise questions relevant to any context where these substances are handled:

• Impurity profiles: FDA states that compounded LL-37 and PEG-MGF may have complexities with regard to peptide-related impurities and API characterization, and that compounded injectable GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. Laboratories sourcing these materials for research should request batch-specific certificates of analysis (COA) with HPLC purity data, impurity profiles, and test methods. See our guide: How to Read a Peptide COA.
• Reference standards: As the USP November 3, 2026 statement noted for the six July 2026 PCAC peptides, quality assurance depends on reference standards and monographs. Laboratories should ask suppliers what reference standard was used for identity and purity testing, and whether it is traceable to a recognized authority (USP, NIST) or is an in-house standard.
• Safety data gaps: FDA's statements—particularly for Dihexa (no human exposure data via any route) and PEG-MGF (no human exposure data)—highlight the limited safety information available. Researchers working with these materials should follow institutional biosafety and chemical handling protocols, document procurement and protocol approvals, and maintain clear RUO labeling and storage records. See our RUO documentation checklist.
• Adverse event case reports: FDA's statement on Melanotan II cites published case reports of serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. These underscore the importance of careful handling, clear RUO labeling, and institutional oversight.

RUO suppliers and laboratory procurement teams should ensure suppliers maintain clear RUO positioning, do not make therapeutic claims, provide batch-specific COA documentation, and focus on institutional customers. The regulatory landscape for peptides is evolving rapidly; laboratories should stay informed and document procurement decisions carefully.

All claims in this analysis are sourced from primary FDA documents and legal commentary:

• FDA Advisory Committee Page: U.S. Food and Drug Administration, "Meeting of the Pharmacy Compounding Advisory Committee." https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee (accessed November 9, 2026).
• FDA Safety Risk Page: U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks (accessed November 9, 2026).
• FDA Bulk Drug Substances Document (Updated May 14, 2026): U.S. Food and Drug Administration, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act." https://www.fda.gov/media/94155/download (Updated May 14, 2026).
• 21 CFR 216.23 (503A Bulks List): U.S. Electronic Code of Federal Regulations, title 21, chapter I, subchapter C, part 216, subpart B, section 216.23. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 (accessed November 9, 2026).
• Federal Register Notice (October 30, 2026): Department of Health and Human Services, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496, 91 FR 68526-68527. https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
• FDA Warning Letter (August 24, 2026): U.S. Food and Drug Administration, "Warning Letter: NuScience Peptides LLC 733652." https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026 (August 24, 2026).
• Orrick Legal Commentary: Orrick, Herrington & Sutcliffe LLP, "FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings" (April 2026). https://www.orrick.com/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings

Related PurePep Vital Content

• HHS Peptide Enforcement Discretion Policy (Oct 2026) — Full Analysis
• USP Statement on HHS Peptide Policy — Quality Standards Gap
• FDA Peptide Reclassification 2026 — Complete Timeline
• Research Peptide Regulatory Timeline (2023–2026)
• Regulatory Resources Hub
• How to Read a Peptide Certificate of Analysis (COA)
• How to Verify Peptide COA Authenticity
• RUO Documentation Checklist
• LL-37 (Cathelicidin) Research | GHK-Cu | Dihexa | Melanotan II | MGF